Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 10:16:1003-1012.
doi: 10.2147/DMSO.S402618. eCollection 2023.

Effects of Metabolic Syndrome on Cardiovascular Outcomes of Psoriatic Patients with Coronary Artery Disease: A Single Center Retrospective Cohort Study

Lin Zhao #  1 , Lin Sun #  1 , Kunqi Yang  1 , Zuozhi Li  1 , Yan Wang  1 , Tianjie Wang  1 , Man Wang  1 , Yan Zeng  1 , Xianliang Zhou  1 , Weixian Yang  1
Affiliations

Effects of Metabolic Syndrome on Cardiovascular Outcomes of Psoriatic Patients with Coronary Artery Disease: A Single Center Retrospective Cohort Study

Lin Zhao et al. Diabetes Metab Syndr Obes. .

Abstract

Background: Psoriasis is associated with an increased prevalence of cardiovascular risk factors, including metabolic syndrome (MetS). To date, it is unclear whether MetS causes differences in cardiovascular outcomes in psoriatic patients with coronary artery disease.

Methods: We conducted a retrospective cohort study to determine the effects of MetS in psoriatic patients with coronary artery disease. Comparisons were made between patients with and without MetS. Cox regression analysis and Kaplan-Meier survival analysis were used to evaluate the association between variables.

Results: Of the 307 psoriatic patients with coronary artery disease, 94 met criteria (30.6%) for MetS. Individuals with MetS were more likely to be female (p <0.001). Levels of platelet counts and high-sensitivity C-reactive protein were higher in the MetS group (p = 0.038 and 0.005, respectively). After a mean follow-up of 35.32 months, major adverse cardiovascular events (MACEs) and non-fatal myocardial infarction were more likely in the MetS than the non-MetS group (33.3% vs 20.6%, p = 0.02; 26.4% vs 15.7%, p = 0.032, respectively). Kaplan-Meier estimates showed the same trend. Cox regression analysis showed that MetS (hazard ratio 1.738; 95% confidence interval 1.045-2.891; p = 0.033) and left ventricular ejection fraction (hazard ratio 0.968; 95% confidence interval 0.945-0.991; p = 0.006) were associated with an increased risk of MACEs.

Conclusion: In psoriatic patients with coronary artery disease, MetS independently predicted MACEs. In addition, left ventricular ejection fraction was negatively associated with an increased risk of MACEs. To reduce the cardiovascular disease risk, it is necessary to increase awareness of MetS in psoriatic patients with coronary artery disease.

Keywords: MACEs; cardiovascular outcomes; coronary artery disease; metabolic syndrome; psoriasis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow chart showing the selection of patients.
Figure 2
Figure 2
Kaplan–Meier estimated event rates for patients with and without MetS. (A) Survival curves for the outcome of MACE in patients between two groups; (B) survival curves for the outcome of all-cause death in patients between two groups; (C) survival curves for the outcome of non-fatal myocardial infarction in patients between two groups; (D) survival curves for the outcome of non-fatal stroke in patients between two groups; (E) survival curves for the outcome of unplanned revascularization in patients between two groups; (F) survival curves for the outcome of re-hospitalization in patients between two groups.
See this image and copyright information in PMC

References

    1. Expert Panel on Detection E. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285(19):2486–2497. doi:10.1001/jama.285.19.2486 - DOI - PubMed
    1. Lu J, Wang L, Li M, et al. Metabolic syndrome among adults in China: the 2010 China noncommunicable disease surveillance. J Clin Endocrinol Metab. 2017;102(2):507–515. doi:10.1210/jc.2016-2477 - DOI - PubMed
    1. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288(21):2709–2716. doi:10.1001/jama.288.21.2709 - DOI - PubMed
    1. Hess PL, Al-Khalidi HR, Friedman DJ, et al. The metabolic syndrome and risk of sudden cardiac death: the atherosclerosis risk in communities study. J Am Heart Assoc. 2017;6(8). doi:10.1161/JAHA.117.006103 - DOI - PMC - PubMed
    1. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56(14):1113–1132. doi:10.1016/j.jacc.2010.05.034 - DOI - PubMed